Ian Karp | Senior Vice President, Investor Relations and Corporate Communications |
John Leonard | Chief Executive Officer |
David Lebwohl | Chief Medical Officer |
Laura Sepp-Lorenzino | Chief Scientific Officer |
Glenn Goddard | Chief Financial Officer |
Maury Raycroft | Jeffries |
Greg Harrison | Bank of America |
Swapnil Malekar | Piper Sandler |
Terence Flynn | Morgan Stanley |
Yanan Zhu | Wells Fargo |
Rick Bienkowski | Cantor Fitzgerald |
Raju Prasad | William Blair |
Dae Gon Ha | Stifel |
Debjit Chattopadhyay | Guggenheim |
Rich Law | Credit Suisse |
Jay Olson | Oppenheimer |
Brian Cheng | JP Morgan |
Joseph Thome | Cowen & Company |
Good morning and welcome to the Intellia Therapeutics' Fourth Quarter and Full Year 2022 Financial Results Conference Call. My name is Drew and I will be your conference operator today.
Following formal remarks, we will open the call up for a question-and-answer session. This conference is being recorded at the Company's request and will be available at the Company's website following the end of the call.
As a reminder, all participants are currently in a listen-only mode.